Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aurore Douge

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Bulletin Du Cancer|August 19, 2018
[The CAR-T cells are here]Carolyne Croizier, Aurore Douge, Jacques-Olivier Bay, et al.
American Journal of Hematology|October 30, 2018
Outcome and impact of post-remission strategy after MIDAM regimen in patients with relapsing or refractory acute myeloid leukemiaSalem Bahashwan, Cécile Moluçon-Chabrot, Eric Hermet, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Bulletin Du Cancer|August 19, 2018
[The CAR-T cells are here]Carolyne Croizier, Aurore Douge, Jacques-Olivier Bay, et al.
American Journal of Hematology|October 30, 2018
Outcome and impact of post-remission strategy after MIDAM regimen in patients with relapsing or refractory acute myeloid leukemiaSalem Bahashwan, Cécile Moluçon-Chabrot, Eric Hermet, et al.
Pageof 1